Company profile
Nuwellis, Inc.
NASDAQ: NUWE · Healthcare · Medical - Devices
#652 of 1,417 Healthcare companies by revenue35th-percentile growth
EA Score
43DFH 31DQ 55GM 56SS 44
v0.1 · 65/100 weight · provisional
↑ growth stability, disclosure history · ↓ return on equity, return on assets
Methodology →Revenue TTM
$9.0M
Rev growth YoY (TTM)
+8.4%
Net income (FY)
-$17.5M
Employees
38
as of 2026-08-26
Market cap
$88.4k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$8.3M$8.3M2025
Net income-$17.5M-$17.5M2025
Operating income-$11.1M-$11.1M2025
Total assets$6.1M$6.1M2025
Liabilities$3.5M$3.5M2025
Equity$2.6M$2.6M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Nuwellis, Inc.’s revenue?
Nuwellis, Inc. booked $8.3M in FY2025 revenue, contracting 5.4% year over year — slower than 65% of Healthcare companies we track, at a -211.9% net margin.
Peers · Healthcare
Herbal Dispatch Inc.52DMJardin Group, Inc.——Aspyra Inc.——Solid Biosciences Inc.41DNextleaf Solutions Ltd.57CCoya Therapeutics, Inc.48DNeighbors
Hennepin →Key facts
CEOMichael McCormick
SectorHealthcare
IndustryMedical - Devices
HeadquartersEden Prairie, MN
ExchangeNASDAQ: NUWE
Employees38
IPO date2012-02-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.